{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:57:33Z","timestamp":1789178253684,"version":"build-2803163510"},"reference-count":29,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T00:00:00Z","timestamp":1528156800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0365-3","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T13:38:35Z","timestamp":1528205915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report"],"prefix":"10.1136","volume":"6","author":[{"given":"Masood","family":"Sadaat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sekwon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"key":"365_CR1","doi-asserted-by":"publisher","unstructured":"Daver N, McClain K, Allen CE, et al. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017; \n                    https:\/\/doi.org\/10.1002\/cncr.30826\n                    \n                  .","DOI":"10.1002\/cncr.30826"},{"issue":"1","key":"365_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/asheducation-2011.1.178","volume":"2011","author":"S Weitzman","year":"2011","unstructured":"Weitzman S. Approach to Hemophagocytic syndromes. Hematology. 2011;2011(1):178\u201383. \n                    https:\/\/doi.org\/10.1182\/asheducation-2011.1.178.","journal-title":"Hematology"},{"key":"365_CR3","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","volume":"383","author":"M Ramos-Casals","year":"2014","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, L\u00f3pez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383:1503\u201316. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(13)61048-X\n                    \n                  .","journal-title":"Lancet"},{"issue":"2","key":"365_CR4","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/eji.201646686","volume":"47","author":"S Ammann","year":"2017","unstructured":"Ammann S, Lehmberg K, zur SU, et al. Primary and secondary hemophagocytic lymphohistiocytosis have different patterns of T-cell activation, differentiation and repertoire. Eur J Immunol. 2017;47(2):364\u201373. \n                    https:\/\/doi.org\/10.1002\/eji.201646686\n                    \n                  .","journal-title":"Eur J Immunol"},{"issue":"6","key":"365_CR5","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1309\/AJCP4ZDKJ4ICOUAT","volume":"139","author":"FG Rosado","year":"2013","unstructured":"Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013;139(6):713\u201327.","journal-title":"Am J Clin Pathol"},{"key":"365_CR6","doi-asserted-by":"publisher","unstructured":"Daver N, Kantarjian H. Malignancy-associated haemophagocytic lymphohistiocytosis in adults. Lancet Oncol. 2017; \n                    https:\/\/doi.org\/10.1016\/S1470-2045(17)30004-9\n                    \n                  .","DOI":"10.1016\/S1470-2045(17)30004-9"},{"key":"365_CR7","doi-asserted-by":"publisher","unstructured":"Leick MB, Maus MV. Toxicities associated with immunotherapies for hematologic malignancies. Best Pract Res Clin Haematol. 2018:1\u20130. \n                    https:\/\/doi.org\/10.1016\/j.beha.2018.03.004\n                    \n                  .","DOI":"10.1016\/j.beha.2018.03.004"},{"issue":"4","key":"365_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559\u201374. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv623\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"365_CR9","doi-asserted-by":"publisher","unstructured":"Suarez-Almazor ME, Kim ST, Abdel-Wahab N, Diab A. Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of Cancer. Arthritis Rheum. 2017; \n                    https:\/\/doi.org\/10.1002\/art.40043\n                    \n                  .","DOI":"10.1002\/art.40043"},{"issue":"9","key":"365_CR10","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/art.38690","volume":"66","author":"L Fardet","year":"2014","unstructured":"Fardet L, Galicier L, Lambotte O, et al. Development and validation of the hscore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613\u201320. \n                    https:\/\/doi.org\/10.1002\/art.38690\n                    \n                  .","journal-title":"Arthritis Rheumatol"},{"key":"365_CR11","doi-asserted-by":"publisher","unstructured":"Hejblum G, Lambotte O, Galicier L, et al. A web-based Delphi study for eliciting helpful criteria in the positive diagnosis of hemophagocytic syndrome in adult patients. PLoS One. 2014;9(4) \n                    https:\/\/doi.org\/10.1371\/journal.pone.0094024\n                    \n                  .","DOI":"10.1371\/journal.pone.0094024"},{"key":"365_CR12","doi-asserted-by":"publisher","unstructured":"Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of Hemophagocytic Lymphohistiocytosis. Pediatr Blood Cancer. 2008; \n                    https:\/\/doi.org\/10.1002\/pbc\n                    \n                  .","DOI":"10.1002\/pbc"},{"key":"365_CR13","doi-asserted-by":"publisher","unstructured":"Grang\u00e9 S, Buchonnet G, Besnier E, et al. The use of ferritin to identify critically ill patients with secondary Hemophagocytic Lymphohistiocytosis. Crit Care Med. 2016; \n                    https:\/\/doi.org\/10.1097\/CCM.0000000000001878\n                    \n                  .","DOI":"10.1097\/CCM.0000000000001878"},{"key":"365_CR14","doi-asserted-by":"publisher","unstructured":"Schaer DJ, Schleiffenbaum B, Kurrer M, et al. Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol. 2005; \n                    https:\/\/doi.org\/10.1111\/j.1600-0609.2004.00318.x\n                    \n                  .","DOI":"10.1111\/j.1600-0609.2004.00318.x"},{"key":"365_CR15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01","volume-title":"Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia Key Points","author":"KK Ness","year":"2015","unstructured":"Ness KK, Delany JP, Kaste SC, et al. Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia Key Points; 2015. \n                    https:\/\/doi.org\/10.1182\/blood-2015-01\n                    \n                  ."},{"key":"365_CR16","doi-asserted-by":"publisher","unstructured":"Tamamyan GN, Kantarjian HM, Ning J, et al. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016; \n                    https:\/\/doi.org\/10.1002\/cncr.30084\n                    \n                  .","DOI":"10.1002\/cncr.30084"},{"key":"365_CR17","doi-asserted-by":"publisher","unstructured":"Rosado FGN, Kim AS. Hemophagocytic lymphohistiocytosis. Am J Clin Pathol. 2013; \n                    https:\/\/doi.org\/10.1309\/AJCP4ZDKJ4ICOUAT\n                    \n                  .","DOI":"10.1309\/AJCP4ZDKJ4ICOUAT"},{"key":"365_CR18","doi-asserted-by":"publisher","unstructured":"Otrock ZK, Daver N, Eby CS. Diagnostic challenges of Hemophagocytic Lymphohistiocytosis. Clin Lymphoma, Myeloma Leuk. 2017; \n                    https:\/\/doi.org\/10.1016\/j.clml.2017.02.017\n                    \n                  .","DOI":"10.1016\/j.clml.2017.02.017"},{"key":"365_CR19","doi-asserted-by":"publisher","unstructured":"Wang Y, Wang Z. Treatment of hemophagocytic lymphohistiocytosis. Curr Opin Hematol. 2017; \n                    https:\/\/doi.org\/10.1097\/MOH.0000000000000302\n                    \n                  .","DOI":"10.1097\/MOH.0000000000000302"},{"issue":"2","key":"365_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2006","unstructured":"Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2006;48(2):124\u201331. \n                    https:\/\/doi.org\/10.1002\/pbc.21039.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"365_CR21","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.blre.2016.05.001","volume":"30","author":"A Hayden","year":"2016","unstructured":"Hayden A, Park S, Giustini D, Lee AYY, Chen LYC. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review. Blood Rev. 2016;30(6):411\u201320. \n                    https:\/\/doi.org\/10.1016\/j.blre.2016.05.001\n                    \n                  .","journal-title":"Blood Rev"},{"issue":"19","key":"365_CR22","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.3760\/cma.j.issn.0253-2727.2014.10.006","volume":"126","author":"Y Wang","year":"2016","unstructured":"Wang Y, Wang Z, Huang W, et al. Multi-Center Study of DEP Regimen As a Salvage Therapy for Adult Refractory Hemophagocytic Lymphohistiocytosis. Present 56th ASH Annu Meet December 6\u20139, 2014; San Fr CA Abstr 2748. 2016;126(19):2186\u201393. \n                    https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2014.10.006\n                    \n                  .","journal-title":"Present 56th ASH Annu Meet December 6\u20139, 2014; San Fr CA Abstr 2748"},{"issue":"6","key":"365_CR23","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/annonc\/mdx113","volume":"28","author":"D Shah","year":"2017","unstructured":"Shah D, Shrestha R, Ramlal R, Hatton J, Saeed H. Pembrolizumab associated hemophagocytic lymphohistiocytosis. Ann Oncol. 2017;28(6):1403. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx113\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"365_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.01.063","volume-title":"Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab","author":"I Satzger","year":"2018","unstructured":"Satzger I, Ivanyi P, L\u00e4nger F, et al. Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab; 2018. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2018.01.063\n                    \n                  ."},{"key":"365_CR25","doi-asserted-by":"publisher","unstructured":"Malissen N, Lacotte J, Du-Thanh A, Gaudy-Marqueste C, Guillot B, Grob JJ. Macrophage activation syndrome: a new complication of checkpoint inhibitors. Eur J Cancer. 2017; \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.02.016\n                    \n                  .","DOI":"10.1016\/j.ejca.2017.02.016"},{"key":"365_CR26","doi-asserted-by":"publisher","unstructured":"Takeshita M, Anai S, Mishima S, Inoue K. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression. Ann Oncol. 2017 \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw537\n                    \n                  .","DOI":"10.1093\/annonc\/mdw537"},{"key":"365_CR27","doi-asserted-by":"publisher","unstructured":"Zheng PP, Kros JM, Li J. Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov Today. 2018. \n                    https:\/\/doi.org\/10.1016\/j.drudis.2018.02.012\n                    \n                  .","DOI":"10.1016\/j.drudis.2018.02.012"},{"key":"365_CR28","doi-asserted-by":"publisher","unstructured":"Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J (United States). 2014; \n                    https:\/\/doi.org\/10.1097\/PPO.0000000000000035\n                    \n                  .","DOI":"10.1097\/PPO.0000000000000035"},{"key":"365_CR29","doi-asserted-by":"publisher","unstructured":"Saarela M, Senthil K, Jones J, et al. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology. 2018; \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000005420\n                    \n                  , \n                    https:\/\/doi.org\/10.1212\/WNL.0000000000005420\n                    \n                  .","DOI":"10.1212\/WNL.0000000000005420"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0365-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0365-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0365-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:43:37Z","timestamp":1601055817000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0365-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,5]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["365"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0365-3","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,5]]},"assertion":[{"value":"11 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"49"}}